Alpha 2.0
Login Register
» Authors » Samy Mohamady

Samy Mohamady

Explore the profile of Samy Mohamady including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 128
Followers 0
Related Specialties
Chemistry
Biochemistry
General Medicine
Top 10 Co-Authors
Scott D Taylor
Bassem H Naguib
Khaled El-Adl
Ahmed F Khalil
Moataz S Hendy
Noura S Hanafy
David L Jakeman
Sanadelaslam S A El-Hddad
Mohamed S Nafie
Moataz A Shaldam
Published In
Bioorg Chem
Org Lett
J Org Chem
ACS Omega
RSC Adv
Affiliations
Soon will be listed here.
Recent Articles
1.
New series of 4,6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR/VEGFR-2 inhibitors
Mostafa Y, Assoud J, Desoky A, Mohamady S, Mohamed N, Salem O, et al.
Front Chem . 2024 Nov; 12:1498104. PMID: 39569013
Introduction: We developed and produced a new series of 4,6-diaryl-pyrimidines as antiproliferative agents targeting EGFR/VEGFR-2. Methods: The antiproliferative efficacy of the novel targets was assessed against a panel of 60...
2.
Fragment-based design and synthesis of coumarin-based thiazoles as dual c-MET/STAT-3 inhibitors for potential antitumor agents
Naguib B, Elsebaie H, Nafie M, Mohamady S, Albujuq N, Samir Ayed A, et al.
Bioorg Chem . 2024 Aug; 151:107682. PMID: 39137597
c-MET and STAT-3 are significant targets for cancer treatments. Here, we describe a class of very effective dual STAT-3 and c-MET inhibitors with coumarin-based thiazoles (3a-o) as its scaffold. Spectroscopic...
3.
Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR and EGFR: design, synthesis, ADMET and molecular docking
Aljohani A, El-Adl K, Almohaywi B, Alatawi O, Alsulaimany M, El-Morsy A, et al.
RSC Adv . 2024 Mar; 14(12):7964-7980. PMID: 38454937
Fifteen new iodoquinazoline derivatives, 5a,b to 18, are reported in this study and their anticancer evaluation as dual inhibitors of EGFR and EGFR. The new derivatives were designed according to...
4.
2-Thioxo-3,4-dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFR and VEGFR-2 inhibitors: Design, synthesis, docking, and anticancer evaluations
El-Gaby M, Reheim M, Akrim Z, Naguib B, Saleh N, El-Adasy A, et al.
Drug Dev Res . 2024 Feb; 85(1):e22143. PMID: 38349267
The effectiveness of a new series of thiopyrimidine and thiourea containing sulfonamides moieties was tested on HCT-116, MCF-7, HepG2, and A549. HepG2 cell line was the one that all the...
5.
Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR and VEGFR-2 inhibitors: design, synthesis, ADMET profile, molecular docking, dynamic simulation and anticancer evaluations
Anwer K, El-Hddad S, Abd El-Sattar N, El-Morsy A, Khedr F, Mohamady S, et al.
RSC Adv . 2023 Dec; 13(50):35321-35338. PMID: 38053688
Novel azobenzene scaffold-joined heterocyclic isoxazole, pyrazole, triazole, and/or triazine moieties have been developed and synthesized utilizing microwave and traditional methods. Our compounds were tested for growth inhibition of A549, MCF-7,...
6.
Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study
Mohamady S, Khalil A, Naguib B, Nafie M, Tawfik H, Shaldam M
Bioorg Chem . 2023 Nov; 143:106988. PMID: 37995644
For the horseshoe tactic to succeed in inhibiting c-Met and Pim-1, the nicotinonitrile derivatives (2a-n) were produced in high quantities by coupling acetyl phenylpyrazole (1) with the proper aldehydes and...
7.
Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis
Khalifa A, Khalil A, Abdel-Aziz M, Albohy A, Mohamady S
Bioorg Chem . 2023 May; 138:106591. PMID: 37201321
Tuberculosis is a worldwide problem that impose a burden on the economy due to continuous development of resistant strains. The development of new antitubercular drugs is a need and can...
8.
Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment
Hanafy N, Aziz N, El-Hddad S, Abdelgawad M, Ghoneim M, Dawood A, et al.
Arch Pharm (Weinheim) . 2023 May; 356(7):e2300137. PMID: 37147779
Novel thiazolidine-2,4-diones have been developed and estimated as conjoint inhibitors of EGFR and VEGFR-2 against HCT-116, MCF-7, A549, and HepG2 cells. Compounds 6a, 6b, and 6c were known to be...
9.
Effect of hydrophobic extension of aryl enaminones and pyrazole-linked compounds combined with sulphonamide, sulfaguanidine, or carboxylic acid functionalities on carbonic anhydrase inhibitory potency and selectivity
Abdelrasheed Allam H, Albakry M, Mahmoud W, Bonardi A, Moussa S, Mohamady S, et al.
J Enzyme Inhib Med Chem . 2023 Apr; 38(1):2201403. PMID: 37078174
Design and synthesis of three novel series of aryl enaminones (- and -) and pyrazole () linked compounds with sulphonamides, sulfaguanidine, or carboxylic acid functionalities were reported as carbonic anhydrase...
10.
Design, Synthesis, and Biological Evaluation of Novel 7-[1,2,4]Triazolo[3,4-][1,3,4]thiadiazine Inhibitors as Antitumor Agents
Ismail M, Mohamady S, Samir N, Abouzid K
ACS Omega . 2020 Aug; 5(32):20170-20186. PMID: 32832771
A series of novel anticancer hydrazinotriazolothiadiazine-based derivatives were designed based on the structure-activity relationship of the previously reported anticancer triazolothiadiazines. These derivatives were synthesized and biologically screened against full NCI-60...